We keep our HOLD rating but lower our target price from €9.50 to €8.50 reflecting our lowered estimates. 3Q25 beat ING estimates but the revenue trend in NL disappointed and showed the early impact from the upcoming pension regulatory changes, which also leads us to lower our estimates for FY26-27F. Brunel has taken additional cost-cutting measures to offset these pressures and to protect margins in NL and Germany. Brunel Germany seems to have stabilised and further supplier rationalisation shou...
Adyen: Preview Investor Day Aperam: In line 3Q25 EBITDA, soft 4Q25 guidance balanced by optimism on EU trade action and FCF beat Brunel: 3Q25 beats; outlook FY25 in line but trend NL and cash position weaker CM.com: Rejects Bird's offer Euronext: Records, beats, buybacks and upgrades GBL: 3Q25 a bit light Kinepolis: Canadian peer Cineplex 3Q25 Results and October 2025 Box office revenue NEPI Rockcastle: COO appointed as new CEO Proximus: Major cut to Global 2026 EBITDA, in line 3Q, 2025 FCF guid...
Brunel Q3 2025 results: Driving operational efficiency Amsterdam, 7 November 2025 – Brunel International N.V. (Brunel; BRNL), a global specialist delivering customised project and workforce solutions to drive sustainable industry transformations through technology and talent, today announced its third quarter and first nine months results. Q3 2025 Key points Revenue of EUR 304.0 million, down 10% (down 7% organically)Gross profit of EUR 56.5 million, down 16% (down 14% organically)Underlying EBIT of EUR 11.9 million, down 31% (down 29% organically)Cost reduction programs delivered EUR 5.1...
Adyen: 3Q25 results – solid net revenue, FY25 guidance reiterated. Aedifica: Guidance raised, positive tenant trends and good portfolio valuation. Ageas: China Taiping Life 3Q25 Solvency much lower, remains solid. Allfunds Group PLC: Strong flows. ASM International: 3Q25 results - disappointing orders, much better margins. Corbion: Iron wills and nerves of steel. Lotus Bakeries: peer Mondelez 3Q25 results. Melexis: 3Q25 results, ongoing gross margin pressure. Staffing: Dutch figs...
We downgrade Brunel from Buy to HOLD as the valuation argument is not strong enough to outweigh the short-term earnings risk we still see in key markets. We have lowered our estimates significantly post 2Q25 results reflecting the lack of a recovery while we see regulatory risks in NL, no signs of a German bazooka to provide support while Global Businesses faces some headwinds in certain regions due to project delays, slower momentum in Americas and Australasia while in general being impacted by...
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
Brunel Q2 and H1 2025 results: Driving efficiency, building resilience Amsterdam, 1 August 2025 – Brunel International N.V. (Brunel; BRNL), a global specialist delivering customised project and workforce solutions to drive sustainable industry transformations through technology and talent, today announced its second quarter and first half 2025 results. Q2 2025 Key points Revenue of EUR 303 million, down 12% (down 7% organically)Gross profit of EUR 52 million, down 20% (down 14% organically)Underlying EBIT of EUR 6.3 million, down 46% (down 27% organically)Additional cost ...
Akzo Nobel: FX drives 2Q25 miss and FY guidance cut. dsm-firmenich: Givaudan 1H25 results. Exor: In talks over Iveco sale. Lotus Bakeries: Peer Lindt & Sprüngli 1H25 results. Proximus: CpaaS peer Sinch 2Q25 results hurt by FX. Signify: 2Q25 Preview, challenges ahead. Var Energi: Promising continuation of dividend. Vopak: Continued story. Wereldhave: Strong operational results, positive market tone, guidance raised. Events Calendar
Brunel will report its 2Q25F/1H25F results on Friday, 1 August before market opening. We expect a weak quarter mainly due to Germany and ongoing soft perm business. As such we lower our FY25-27F EPS estimates by 7%, 6% and 4% respectively. Since we expect no swift recovery in Germany, we believe some further cost savings measures are imminent to protect margins in Germany while keeping the growth potential intact. We keep our BUY rating and target price at €10.50 as we feel we likely modelled in...
Ahold Delhaize: 2Q25 pre-close call feedback. Azelis: Attractive acquisition in personal care Italy. Econocom: Two UK/Ireland AV acquisitions disclosed. Staffing: Better French volumes in May even with easier comps, June outlook sluggish. Staffing: Dutch figs Period 6 volume and revenues weaker on tougher comps. UCB: Trump threatens a 200% tariff on pharmaceutical products
In this report we present our view on the long-term growth prospects for offshore wind in Europe, implications of the energy transition and the role of TSOs, such as Elia Group. We also focus on supply chain beneficiaries in our Benelux coverage. An increasing number of long-term framework contracts should provide improved risk-rewards to the supply chain, in our view. Furthermore, we take a deep dive into growth drivers and long-term financing for Elia Group, beyond the company's current financ...
Colruyt: FY24/25F set to be in line with recently revised guidance. Exor: In search of a €2bn deal. Flow Traders: Sell In May And Go Away. Kinepolis: Peer Cineplex May 2025 box office revenue up 63% YoY, at 81% of 2019 level. Staffing: Dutch Period 5 - May vols up, strong pricing, working days/comps might distort. Staffing: French staffing - strong April data, May outlook also better
A director at Brunel International maiden bought 28,345 shares at 8.880EUR and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.